Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
Cantrixil (TRX-E-002-1)
i
Other names:
TRX-E-002-1, TRXE-002-1 encapsulated in a cyclodextrin envelope, TRX1, TRXE 002 1, TRXE-002, TRXE-002-1, TRXE002, TRX E 002 1
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
Kazia, Vivesto, Yale University
Drug class:
Cell death stimulant
Related drugs:
‹
TEQ103 (1)
CG0070 (1)
DNX-2401 (1)
AMUN-003 (0)
Ad-p53 gene therapy (0)
BI 1821736 (0)
CP-506 (0)
Clostridium novyi-NT (0)
DNX-2440 (0)
synthetic hypericin (0)
KM1 (0)
MV-NIS (0)
ruxotemitide (0)
R130 (0)
RGV004 (0)
TG6050 (0)
VCN-01 (0)
YSCH-01 (0)
BBI-503 (0)
bendamustine hydrochloride (0)
ColoAd1 (0)
PT-112 (0)
RP1 (0)
TEQ103 (1)
CG0070 (1)
DNX-2401 (1)
AMUN-003 (0)
Ad-p53 gene therapy (0)
BI 1821736 (0)
CP-506 (0)
Clostridium novyi-NT (0)
DNX-2440 (0)
synthetic hypericin (0)
KM1 (0)
MV-NIS (0)
ruxotemitide (0)
R130 (0)
RGV004 (0)
TG6050 (0)
VCN-01 (0)
YSCH-01 (0)
BBI-503 (0)
bendamustine hydrochloride (0)
ColoAd1 (0)
PT-112 (0)
RP1 (0)
›
Associations
News
Trials
Filter by
Latest
over4years
[VIRTUAL] TRX-E-002-1 in treatment-refractory ovarian cancer - 3-month follow-up results from a phase I study dose escalation phase (AACR-II 2020)
IP administered TRX-E-002-1 as a first-in-class, dual acting, anti-cancer therapy has preliminary activity for the treatment of platinum resistant ovarian cancer for patients who have demonstrated resistance to a range of prior treatments.
over 4 years ago
P1 data • PARP Biomarker
|
CD44 (CD44 Molecule)
|
Cantrixil (TRX-E-002-1)
over4years
Phase I Study of Cantrixil in Patients With Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer. (clinicaltrials.gov)
P1, N=28, Completed, Kazia Therapeutics Limited | Active, not recruiting --> Completed | Trial primary completion date: Dec 2019 --> Mar 2020
over 4 years ago
Clinical • Trial completion • Trial primary completion date
|
BRCA (Breast cancer early onset)
|
Cantrixil (TRX-E-002-1)
Share via
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login